

corrections in the scientific record noted below, and additional analysis conducted by ORI in its oversight review, ORI found that Dr. Nasser Chegini, retired as a Professor in the Department of Obstetrics and Gynecology, UF, engaged in research misconduct in research supported by National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), grant 2 R01 HD037432.

ORI acknowledges that the following papers were retracted as a result of the institution's investigation:

1. *J Clin Endocrinol Metab* 88(10):4967–4976, 2003. Retraction in: *J Clin Endocrinol Metab* 100(1):318, 2015 Jan.
2. *Reprod Biol Endocrinol* 1:125, 2003. Retraction in: *Reprod Biol Endocrinol* 13:25, 2015 Apr 3.
3. *J Clin Endocrinol Metab* 88(3):1350–1361, 2003. Retraction in: *J Clin Endocrinol Metab* 100(1):318, 2015 Jan.
4. *Hum Reprod* 21(10):2555–2563, 2006. Retraction in: *Hum Reprod* 30(1):249, 2015 Jan (Epub 2014 Nov 6).
5. *Mol Hum Reprod* 12(4):245–256, 2006. Retraction in: *Mol Hum Reprod* 20(12):1258, 2014 Dec (Epub 2014 Nov 13).
6. *Mol Hum Reprod* 13(11):797–806, 2007. Retraction in: *Mol Hum Reprod* 20(12):1259, 2014 Dec (Epub 2014 Nov 13).
7. *Reprod Sci* 15(10):993–1001, 2007. Retraction in: *Reprod Sci* 21(10):1326, 2014 Oct.
8. *J Cell Mol Med* 12(1):227–240, 2008. Retraction in: *J Cell Mol Med* 19(10):2512, 2015 Oct.

ORI found that Respondent engaged in research misconduct by intentionally, knowingly, or recklessly falsifying data that were included in: *J Reprod Immunol* 73(2):118–29, 2007 (hereafter referred to as “*JRI 2007*”). Specifically, ORI found that Respondent falsified data points and standard errors of the mean in bar graphs plotting matrix metalloprotease expression or activity in the following figures of *JRI 2007*:

- Figures 2A, 2B, 2C
- Figures 3A, 3B, 3C
- Figure 4B
- Figure 5C
- Figure 6B
- Figures 7A, 7B, 7C
- Figure 8, middle left panel and lower right panel

Dr. Chegini entered into a Voluntary Settlement Agreement with ORI, in which he voluntarily agreed to the following, beginning on July 12, 2017:

(1) Respondent has not applied for or engaged in U.S. Public Health Service (PHS)-supported research since 2012; Respondent has no intention of applying for or engaging in PHS-supported research or otherwise

working with PHS; however, if within five (5) years of the effective date of the Agreement, the Respondent receives or applies for PHS support, the Respondent agreed to have his research supervised for a period of five (5) years from the date of his employment in a position in which he receives or applies for PHS support and agreed to notify his employer(s)/institution(s) of the terms of this supervision; Respondent agreed that prior to the submission of an application for PHS support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, Respondent shall ensure that a plan for supervision of Respondent's duties is submitted to ORI for approval; the supervision plan must be designed to ensure the scientific integrity of Respondent's research contribution; Respondent agreed that he shall not participate in any PHS-supported research until such a supervision plan is submitted to and approved by ORI; Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan;

(2) Respondent agreed that for a period of five (5) years beginning on the date on which the Respondent receives or applies for PHS support, any institution employing him shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract;

(3) to exclude himself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of five (5) years, beginning with the effective date of the Agreement; and

(4) as a condition of the Agreement, Respondent will request that *J Reprod Immunol* 73(2):118–29, 2007 be retracted.

FOR FURTHER INFORMATION CONTACT:
Director, Office of Research Integrity,
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852, (240) 453–8200.

Kathryn M. Partin,
Director, Office of Research Integrity.

[FR Doc. 2017–16311 Filed 8–2–17; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel NIAID Clinical Trial Implementation Grant (R01).

Date: August 28, 2017.

Time: 12:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Program, Division of Extramural Activities, Room 3F40B National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5036, poeky@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: July 28, 2017.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017–16314 Filed 8–2–17; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; AIDSRRRC Independent SEP.

Date: August 23, 2017.

Time: 1:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Peter R. Jackson, Ph.D., Chief, AIDS Research Review Branch, Scientific Review Program, Division of Extramural Activities, Room #3G20, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5049, pjackson@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: July 28, 2017.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-16313 Filed 8-2-17; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

[Docket No. USCBP-2017-0028]

Commercial Customs Operations Advisory Committee (COAC)

AGENCY: U.S. Customs and Border Protection (CBP), Department of Homeland Security (DHS).

ACTION: Committee Management; Notice of Federal Advisory Committee Meeting.

SUMMARY: The Commercial Customs Operations Advisory Committee (COAC) will hold its quarterly meeting on Wednesday, August 23, 2017, in San Diego, California. The meeting will be open to the public.

DATES: The COAC will meet on Wednesday, August 23, 2017, from 9:00 a.m. to 1:00 p.m. PDT. Please note that the meeting may close early if the committee has completed its business.

Pre-Registration: Meeting participants may attend either in person or via

webinar after pre-registering using one of the methods indicated below:

For members of the public who plan to attend the meeting in person, please register by 5:00 p.m. EDT by August 22, 2017, either online at https://apps.cbp.gov/te_reg/index.asp?w=115; by email to tradeevents@dhs.gov; or by fax to (202) 325-4290. You must register prior to the meeting in order to attend the meeting in person.

For members of the public who plan to participate via webinar, please register online at https://apps.cbp.gov/te_reg/index.asp?w=114 by 5:00 p.m. EDT by August 22, 2017.

Please feel free to share this information with other interested members of your organization or association.

Members of the public who are pre-registered and later need to cancel, please do so by August 22, 2017, utilizing the following links: https://apps.cbp.gov/te_reg/cancel.asp?w=115 to cancel an in person registration or https://apps.cbp.gov/te_reg/cancel.asp?w=114 to cancel a webinar registration.

ADDRESSES: The meeting will be held at the Omni Hotel, 675 L Street, San Diego, CA 92101. For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact Ms. Florence Constant-Gibson, Office of Trade Relations, U.S. Customs & Border Protection, at (202) 344-1440, as soon as possible.

To facilitate public participation, we are inviting public comment on the issues the committee will consider prior to the formulation of recommendations as listed in the "Agenda" section below.

Comments must be submitted in writing no later than August 10, 2017, and must be identified by Docket No. USCBP-2017-0028, and may be submitted by *one (1)* of the following methods:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments.

- *Email:* Tradeevents@dhs.gov. Include the docket number in the subject line of the message.

- *Fax:* (202) 325-4290, Attention: Florence Constant-Gibson.

- *Mail:* Ms. Florence Constant-Gibson, Office of Trade Relations, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW., Room 3.5A, Washington, DC 20229.

Instructions: All submissions received must include the words "Department of Homeland Security" and the docket number (USCBP-2017-0028) for this action. Comments received will be

posted without alteration at <http://www.regulations.gov>. Please do not submit personal information to this docket.

Docket: For access to the docket or to read background documents or comments, go to <http://www.regulations.gov> and search for Docket Number USCBP-2017-0028. To submit a comment, click the "Comment Now!" button located on the top-right hand side of the docket page.

There will be multiple public comment periods held during the meeting on August 23, 2017. Speakers are requested to limit their comments to two (2) minutes or less to facilitate greater participation. Contact the individual listed below to register as a speaker. Please note that the public comment period for speakers may end before the time indicated on the schedule that is posted on the CBP Web page, <http://www.cbp.gov/trade/stakeholder-engagement/coac>.

FOR FURTHER INFORMATION CONTACT: Ms. Florence Constant-Gibson, Office of Trade Relations, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue NW., Room 3.5A, Washington, DC 20229; telephone (202) 344-1440; facsimile (202) 325-4290 OR Ms. Valarie Neuhart, Acting Director and Designated Federal Officer, can also be reached at (202) 344-1440.

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. Appendix. The Commercial Customs Operations Advisory Committee (COAC) provides advice to the Secretary of Homeland Security, the Secretary of the Treasury, and the Commissioner of U.S. Customs and Border Protection (CBP) on matters pertaining to the commercial operations of CBP and related functions within the Department of Homeland Security and the Department of the Treasury.

Agenda

The COAC will hear from the following subcommittees on the topics listed below and then will review, deliberate, provide observations, and formulate recommendations on how to proceed:

1. The Trade Modernization Subcommittee will discuss and deliver recommendations related to the subcommittee's International Engagement and Trade Facilitation Working Group which is identifying examples of best practices in the U.S. and abroad that facilitate trade. The subcommittee will also discuss the progress of the E-Commerce Working Group and will deliver